Olink Proteomics

Executive Summary

Olink Proteomics, now part of Thermo Fisher Scientific, is a leader in high-throughput proteomics through its innovative Proximity Extension Assay (PEA) technology. The platform enables multiplexed detection of up to 5,400 proteins with high specificity and sensitivity from minimal sample volumes, serving both academic research and pharmaceutical development. Since its acquisition in 2023 for approximately $3.1 billion, Olink has benefited from Thermo Fisher’s extensive commercial infrastructure, accelerating the adoption of its proteomic solutions. The company is well-positioned to capitalize on the growing demand for biomarker discovery and precision medicine, with PEA technology increasingly used in large-scale population studies and clinical trials. Olink’s integration into Thermo Fisher’s life sciences portfolio enhances its ability to drive innovation and expand its customer base globally.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation PEA platform with expanded protein coverage90% success
• Q2 2027Major partnership for proteomics-based companion diagnostics in oncology75% success
• Q3 2026Publication of landmark proteomic data from UK Biobank Pharma Proteomics Project95% success